Heng Ren’s activism started in 2015. It began with investments in undervalued Chinese stocks where special situations evolved.
Heng Ren’s activism started in 2015. It began with investments in undervalued Chinese stocks where special situations evolved.
Heng Ren's activism initially focused on undervalued microcap Chinese companies trading on U.S. stock exchanges. Our purpose is to protect our investors' rights, and to realize value in our investments for our investors, and all shareholders.
China Nepstar
After a 91% drop in stock price we demanded the drug store chain make changes to become profitable. Some were implemented and the stock rose. A management buyout was accepted at a price +73% higher than at the start of Heng Ren's initiative.
Exited in 2016
Jiayuan.com
Heng Ren successfully forced a 41% increase in the company's lowball bid to buy out minority shareholders of the Chinese dating site.
Exited in 2015.
Renren Inc.
Heng Ren resisted a management corporate action that hurt minority shareholders. A historic $300 million settlement was paid to shareholders during litigation.
Exited in 2022.
Sinovac Biotech Ltd.
Initially Heng Ren resisted a failed, lowball bid by management in 2016 to buy out minority shareholders. In 2025 Heng Ren pushed for $8.9 billion in dividends from the Chinese vaccine company's enormous COVID-19 profits. A partial $3.9 billion dividend was paid in 2025 to shareholders; Heng Ren continues to push for the unpaid dividends.
Ongoing in 2026.
Now is a good time to get started
If you're ready to get invested in the Next China, we're ready to help you.